Two years ago, confirming amyloid pathology meant either a lumbar puncture or a PET scan costing several thousand dollars out of pocket — and for many families, that cost ended the conversation before it started. Today, high-sensitivity plasma p-tau217 assays — a routine blood draw — can confirm amyloid status with roughly 90% accuracy in hands of validated clinical labs. That single change has transformed how Alzheimer's trial enrollment actually works. Families who call a research site move from "interested" to "formally screened" in weeks, not months. More of them qualify, and fewer of them face the logistical cliff edge that used to stop enrollment cold. If you're exploring trial participation in 2026, understanding that this shift happened — and what it means for the sequence of steps ahead of you — is the right place to start.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
The lecanemab and donanemab approvals settled a 20-year argument: clearing amyloid does slow disease progression, at least in the early stages. The 27% CDR-SB slowing in CLARITY-AD and the 35% iADRS slowing in TRAILBLAZER-ALZ 2 weren't transformative cures, but they proved the amyloid hypothesis was fundamentally right. The 2026 trial landscape builds forward from that proof — next-generation antibodies engineered for fewer ARIA events, anti-tau agents attacking the second pathological hallmark, and prevention trials enrolling cognitively normal adults who carry amyloid burden but haven't yet lost neurons that can't be recovered. The window these trials are targeting has shifted earlier than most families realize, and the screening process has gotten meaningfully less invasive.
ClinicalMetric Analysis
- ARIA (amyloid-related imaging abnormalities) appears in approximately 35% of lecanemab trial participants and substantially higher rates in APOE4 carriers — MRI monitoring is required by REMS and should be treated as a clinical standard, not a research-only requirement. APOE4 homozygotes in CLARITY-AD had ARIA-E (edema) rates exceeding 40% and ARIA-H (microhemorrhage) rates exceeding 60% — rates high enough that several expert groups have questioned whether APOE4 homozygotes should receive lecanemab at all outside the context of closely monitored clinical trials with frequent MRI. The current REMS requires baseline MRI before treatment initiation and MRI at months 1, 3, 5, 7, and 14, with dose interruption protocols for symptomatic ARIA. Prescribing physicians who don't have systems for monitoring and acting on ARIA findings — including weekend radiology coverage that can review urgent MRI results — are not in a position to safely prescribe lecanemab regardless of patient APOE4 status.
- Plasma p-tau217 assays have compressed the Alzheimer's trial screening timeline from months (PET scheduling + out-of-pocket costs) to weeks — and for prevention trials, this specifically changes who enters the screening funnel for the first time. Blood-based biomarker validation (Lilly's AHEAD 3-45, A4 extension studies, ALZpath p-tau217 assay data) shows approximately 90% concordance with amyloid PET at validated labs. The practical change is significant: families with strong familial Alzheimer's history who want to know their amyloid status before deciding about prevention trial participation previously faced a $3,000–$7,000 out-of-pocket amyloid PET scan. High-sensitivity plasma p-tau217 through a validated clinical lab costs approximately $200–$400 and provides an equivalent answer for most patients. This doesn't eliminate PET from the workflow — many trials still require confirmatory PET for enrollment — but it allows families to make an initial informed screening decision based on a blood draw rather than committing to PET scan logistics before knowing whether amyloid burden is present.
- Prevention trial participation for cognitively normal adults requires a 4–6 year commitment during years when the participant feels completely healthy — and participants should understand that even if the drug works, the benefit may not be personally apparent during their participation period. The A3, AHEAD 3-45, and similar prevention trials enroll cognitively normal adults with amyloid burden who may be years away from any symptomatic decline. The rationale is compelling: intervene before neurons are lost and the window for meaningful modification closes. But participants spend 4–6 years attending quarterly visits, undergoing infusions, and receiving MRI monitoring — without the health-related motivation that drives participation for symptomatic patients. The most realistic expectation for participants in a positive prevention trial is that they will have contributed to evidence that benefits others, and that their individual cognitive trajectory may be better than it would have been — but the effect will be subtle relative to what they would see without treatment during the participation window. Families should discuss this honestly before a cognitively normal adult commits to multi-year prevention trial participation.
Why the Field Finally Moved to Disease Modification — and What That Actually Proved
For decades, Alzheimer's trials tested symptomatic agents — acetylcholinesterase inhibitors, memantine, various combinations. They worked modestly and temporarily. The theoretical case for disease modification was always compelling: if amyloid plaques and tau tangles are the cause, remove them before the neurons they're destroying are gone. But executing that idea took 30 years of failed trials and roughly $40 billion in industry investment before lecanemab's CLARITY-AD data changed the field's calculus.
CLARITY-AD (NCT03887455) enrolled 1,795 participants with early Alzheimer's disease — confirmed by amyloid PET or CSF biomarkers — and showed lecanemab reduced the CDR-SB by 27% relative to placebo over 18 months. The FDA granted traditional approval in July 2023. Donanemab followed with TRAILBLAZER-ALZ 2 (NCT04437511): 35% slowing on the iADRS composite in participants with low-to-medium tau burden, and notably, the highest-activity amyloid clearance of any antibody studied to date — 76% of participants reached amyloid negativity on PET by 12 months. Both approvals came with important caveats. The absolute clinical differences are modest. Neither drug halts progression. But both demonstrated that the biology is tractable, and that confirmation: that proof of concept is what unlocked the current generation of trials.
Current Phase 3 programs are asking what comes next. Can better amyloid clearance, faster clearance, or combination approaches targeting amyloid plus tau produce bigger effects? And critically — does starting treatment before any symptoms appear at all produce the most durable outcomes? That last question drives the entire prevention trial architecture.
The Screening Cascade: What to Actually Expect
This is where practical mechanics matter most. Alzheimer's trial screening in 2026 is a multi-stage process, and knowing the sequence prevents wasted time for everyone involved.
- Plasma p-tau217 or p-tau181 blood test: For most trials, this is now the first biomarker gate. A positive result — elevated p-tau217 — predicts amyloid positivity on PET with roughly 87–90% accuracy in validated assays from Quest or Fujirebio. It doesn't fully replace imaging, but it does serve as a rapid triage that spares many patients the time and cost of PET scans they'd fail anyway.
- Amyloid PET or CSF confirmation: Most interventional trials still require confirmatory PET imaging before enrollment. Some protocols accept CSF Aβ42/40 ratio as an alternative. Crucially, PET scans are typically provided at no cost by the trial sponsor — this is one of the most tangible direct benefits of participation, since out-of-pocket amyloid PET can exceed $5,000 in clinical settings.
- APOE-ε4 genotyping: Every amyloid-targeting antibody trial genotypes participants. Homozygous ε4 carriers face a 3–4x higher rate of ARIA-E than non-carriers. Some trials dose-escalate differently in ε4 homozygotes; others cap their enrollment at a defined percentage of homozygotes to preserve the trial's safety profile. This is disclosed in informed consent and affects dosing decisions — not necessarily your eligibility to participate.
- Cognitive and functional assessments: The MMSE, CDR, and ADAS-Cog are standard. Prevention trials enrolling cognitively normal adults use more sensitive composite measures — such as the Alzheimer's Prevention Initiative Composite Cognitive test (APCC) — specifically designed to detect early change before clinical decline is visible.
- Baseline MRI: All antibody trials require baseline MRI to identify pre-existing microhemorrhages or superficial siderosis that would preclude safe treatment. This is a safety screen, not just a formality.
The Study Partner Requirement — More Consequential Than Most Families Expect
Every Alzheimer's trial requires a designated Study Partner, and this disqualifies more families than any biomarker criterion. The Study Partner must spend at least 10 hours per week with the participant, attend every clinical visit, and independently complete observer-rated assessments of daily functioning. This isn't bureaucratic box-checking. It's structural.
Here's why: the primary endpoints of most disease-modification trials include functional outcomes — the CDR-SB, the ADCS-ADL, the iADRS — that require informant report, not just patient self-report. A participant who lives alone, or whose spouse is also cognitively impaired, may be biomarker-positive and clinically eligible on every other dimension but still cannot enroll. This is worth clarifying at the first phone call with a research site, before investing any time in the biomarker screening cascade. Save yourself and the site team a trip.
- Who qualifies: A spouse, adult child, sibling, close friend, or consistent paid caregiver who has regular contact and can reliably report behavioral and functional changes. The definition is practical, not legalistic — what matters is reliability and availability.
- Caregiver burden instruments: Many trials now include the Zarit Burden Interview or NPI-Q as secondary endpoints or safety measures. Retention of the participant-partner dyad over long study periods is a recognized operational challenge, and trial teams generally have experience supporting partners through it.
- Compensation: Study partners receive reimbursement for travel and time at clinical visits even though they're not the enrolled participant. In long trials with frequent visits, this can represent meaningful financial support.
Study Types and Compensation Overview
| Study Type | Target Pathology | Method | Est. Duration | Compensation / Benefits |
|---|---|---|---|---|
| Prevention | Amyloid Beta | IV Infusion | 24–48 Months | Free MRI / PET Scans |
| Tau-Targeting | Tau Tangles | Intrathecal | 18 Months | Concierge Travel |
| Neuro-Repair | Synaptic Plasticity | Oral Tablet | 12 Months | Comprehensive Neuro-Exam |
ARIA: The Safety Signal That Shapes Every Amyloid Trial
ARIA — Amyloid-Related Imaging Abnormalities — is the dominant safety consideration in every amyloid-clearing antibody program. Understanding it correctly matters when weighing trial participation, because the way it's often described creates either too much alarm or too much reassurance. ARIA comes in two forms: ARIA-E (brain edema visible on FLAIR MRI) and ARIA-H (hemosiderin deposits, microhemorrhages on GRE/SWI). In CLARITY-AD, ARIA occurred in about 21% of treated participants versus 9% on placebo. Most events were asymptomatic — detected only on protocol surveillance MRIs. Symptomatic ARIA occurred in roughly 3% of treated participants.
The management protocol in current trials is protocol-specific but follows a general pattern:
- MRI monitoring every 4–8 weeks during the initial dosing phase, then quarterly — the schedule is intensive, and the MRI costs alone can reach $15,000–$30,000 over a 24-month study, all provided free
- Pre-specified dose hold or discontinuation criteria by ARIA grade: asymptomatic Grade 1–2 typically allows a dose hold with re-escalation; symptomatic or severe ARIA leads to permanent discontinuation
- APOE-ε4 homozygotes face approximately 33–40% ARIA rates versus ~10% in non-carriers — a risk-benefit conversation that belongs in informed consent, handled explicitly, not buried in supplemental data
The real-world implication: the monitoring is intensive, but it's a reason trials provide it free. You're getting quarterly neuroimaging at sponsor cost as a standard part of the protocol. That has standalone clinical value even for participants who never develop ARIA.
Finding the Right Trial — and What the Process Actually Looks Like
The Alzheimer's Association TrialMatch (alz.org/trialmatch) and ClinicalTrials.gov remain the starting points. For prevention trials — enrolling cognitively normal adults at elevated biological risk — the A4 Study established the model: blood biomarker screen first, confirmatory PET if positive. The A45 trial (NCT04468659), testing solanezumab in amyloid-positive cognitively unimpaired adults, follows this model. Several active prevention platforms are running concurrently as of 2026, targeting the pre-symptomatic window that we now have the biomarker tools to actually identify.
One practical thing worth knowing: most major Alzheimer's research centers now have dedicated clinical trial navigators. A 30-minute call with a navigator at an academic memory center can tell you which currently-enrolling trials you might realistically qualify for, what biomarker tests you'd need, and whether your Study Partner situation is workable. That call is free. It saves time. And it's a far more efficient first step than trying to decode protocol eligibility language on your own at 11pm on ClinicalTrials.gov.
Frequently Asked Questions
What is the difference between lecanemab and donanemab for Alzheimer's?
Both are anti-amyloid monoclonal antibodies now FDA-approved for early Alzheimer's. Lecanemab (Leqembi) targets soluble and insoluble amyloid protofibrils and is given every 2 weeks IV. Donanemab (Kisunla) targets plaque-bound amyloid and is given monthly IV until plaque clearance — then potentially discontinued. Both slow progression by ~25-35% in early-stage disease. Choice depends on APOE4 status, ARIA risk, and infusion schedule preference.
What does "disease-modifying" mean in Alzheimer's treatment?
Disease-modifying treatments (DMTs) slow or stop the underlying pathological process — amyloid accumulation, tau tangles, neuroinflammation — rather than only managing symptoms. Approved DMTs (lecanemab, donanemab) reduce amyloid plaques and slow cognitive decline by months in early-stage patients. They do not reverse existing damage or restore lost memory, but they extend the period of mild impairment.
Who qualifies for anti-amyloid therapy and how is eligibility confirmed?
Qualifying criteria: confirmed early symptomatic Alzheimer's (MCI or mild dementia stage), positive amyloid confirmation via PET scan or CSF biomarkers (Abeta42/40 ratio, p-tau), and no significant ARIA on baseline MRI. APOE4 genotyping is required — homozygous APOE4/4 carriers face higher ARIA risk. Most academic memory centers and some community neurologists can conduct the full workup.